Suboptimal response to GnRHa long protocol is associated with a common LH polymorphism

• Published in: Reproductive biomedicine online 2009, Vol.18 (1), p.9-14
• Main Authors: Alviggi, C, Clarizia, R, Pettersson, K, Mollo, A, Humaidan, P, Strina, I, Coppola, M, Ranieri, A, D'Uva, M, De Placido, G
• Format: Article
• Language: English
• Subjects: Adult; Amino Acid Substitution - physiology; Clinical Trials as Topic; Drug Resistance - genetics; Estradiol - blood; Female; Fertilization in Vitro - methods; Gene Frequency; Gonadotropin-Releasing Hormone - analogs & derivatives; Gonadotropin-Releasing Hormone - therapeutic use; Humans; immunoassays; IVF; Luteinizing Hormone - genetics; Obstetrics and Gynecology; Ovulation - blood; Ovulation - genetics; Ovulation Induction - methods; pharmacogenomics; polymorphism; Polymorphism, Single Nucleotide - physiology; poor responders; Pregnancy; Recombinant Proteins - therapeutic use; Retrospective Studies; Young Adult; β-subunit variant
• ISSN: 1472-6483; 1472-6491
• DOI: 10.1016/S1472-6483(10)60418-X

Abstract The aim of this observational preliminary trial was to estimate the association between the most common polymorphism of LH (LH-β variant: v-βLH), with different profiles of ovarian response to recombinant human FSH (rhFSH). A total of 60 normogonadotrophic patients undergoing a gonadotrophin-releasing hormone analogue long down-regulation protocol followed by stimulation with recombinant human FSH (rhFSH) for IVF/intracytoplasmic sperm injection, and in whom at least five oocytes were retrieved were retrospectively included. On the basis of the total rhFSH consumption, patients were divided into three groups: Group A: 22 women requiring a cumulative dose of rhFSH >3500 IU; Group B: 15 patients requiring 2000–3500 IU; Group C (control): 23 women requiring